使用抗人GPV1抗体抑制血小板聚集

本发明涉及用于治疗有此需要的受试者中GPVI相关病症的与人糖蛋白VI(hGPVI)结合的分离的人源化蛋白质，其中所述分离的人源化蛋白质在至少2小时期间、优选在4至6小时期间施用于受试者。 The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized pr...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageChinese
Published 04.06.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:本发明涉及用于治疗有此需要的受试者中GPVI相关病症的与人糖蛋白VI(hGPVI)结合的分离的人源化蛋白质，其中所述分离的人源化蛋白质在至少2小时期间、优选在4至6小时期间施用于受试者。 The present invention relates to an isolated humanized protein binding to human Glycoprotein VI (hGPVI) for treating a GPVI-related condition in a subject in need thereof, wherein said isolated humanized protein is to be administered during at least 2 hours to the subject, preferably during at least 4 to 6 hours.
Bibliography:Application Number: CN20188010227